×
切換帳號
FAQ
新手指南
FAQ常見問題
學術會議
影音網
登入
×
全站搜尋
搜尋
台灣泌尿科醫學會E-School
登入
FAQ
新手指南
FAQ常見問題
學術會議
影音網
到官網
Home
到官網
Home
知識庫
目錄總覽
文件總覽
最新討論
目錄 / 資料夾
學術活動與演講
年會
2025半年會
摘要
2024年會
摘要
2024半年會
摘要
2023年會
摘要
2023半年會
摘要
2022年會
摘要
2021年會
摘要
2021半年會
摘要
2020年會
摘要
2020半年會
摘要
2019年會
摘要
2019半年會
摘要
2018年會
摘要
2018半年會
摘要
2017年會
摘要
2017半年會
摘要
2016年會
摘要
2016半年會
摘要
2015年會
摘要
新手指南與FAQ
知識庫
最新上傳
最新上傳
(
熱門
)
最新上傳
(
熱門
)
MP07-02: Therapeutic efficacy of 180-W greenlight xps vaporization of the prostate for the storage symptoms concomitant with benign prostatic obstruction and a search for outcome predictors
2022-06-07
MP07-01: The therapeutic effects of peptide decoy-loaded hydrogel in mice with bladder outlet obstruction-induced bladder injury
2022-06-07
MP06-10: Characteristics of mCRPC patients received Abiraterone acetate plus prednisolone and Enzalutamide before chemotherapy
2022-06-07
MP06-09: KCGMH experience and meta-analysis: 6-cycle complete rate of Radium-223 therapy in Mcrpc patients with different treatment sequences
2022-06-07
MP06-08: Treatment strategy and systemic review with PSMA PET/CT scan in progressive advanced prostate cancer
2022-06-07
MP06-07: Oncological and functional outcomes in high risk and very high risk prostate cancer patients receiving robotic-assisted radical prostatectomy
2022-06-07
MP06-06: The analysis of concordance rates between cancer stage of MR/US fusion prostate biopsy and radical prostatectomy specimen
2022-06-07
MP06-05: Retzius-sparing robot-assisted radical prostatectomy and extended pelvic lymph node dissection for very high-risk prostate cancer
2022-06-07
MP06-04: Hyperforin induces extrinsic/intrinsic apoptosis signaling and inhibits NF-кB for metastasis suppression in prostate cancer cells
2022-06-07
MP06-03: Real world experience of androgen deprivation therapy associated bone fracture risk in newly diagnosed prostate cancer patients
2022-06-07
MP06-02: A single center experience of Abiraterone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel based chemotherapy
2022-06-07
MP06-01: Is extraperitoneal extended pelvic lymph node dissection adequate during robotic assisted radical prostatectomy for intermediate and high risk localized prostate cancer?
2022-06-07
MP05-10: Thrombospondin-4 induces lymphangiogenesis by lymphatic endothelial cell recruitment in bladder tumor
2022-06-07
MP05-09: Suppression of tumor characteristics of urothelial carcinoma cells by berberrubine and resveratrol by GSTM2 induction
2022-06-07
MP05-08: Efficiency and prognosis of enucleation turbt versus traditional turbt– VGHTC experience
2022-06-07
MP05-07: Demethoxycurcumin induces apoptosis in HER2 overexpressing bladder cancer cells through degradation of HER2 and inhibiting the PI3K/Akt pathway
2022-06-07
MP05-06: Validation of neutrophil to lymphocyte ratio for prognosis and treatment selection in muscle invasive bladder cancer: A single-institutional longitudinal study
2022-06-07
MP05-05: Clinical outcomes of plasmacytoid urothelial carcinoma of urinary bladder: A single institution experience
2022-06-07
MP05-04: Effect of Metformin on overall survival of upper tract urothelial carcinoma in patients with type 2 diabetes
2022-06-07
MP05-03: Influence of novel inflammatory biomarkers on prediction for patients with upper tract urothelial carcinoma
2022-06-07
MP05-02: Melatonin suppresses tumor malignancy through the NF-KB/P65/HIF-1a pathway in urothelial carcinoma
2022-06-07
MP05-01: Survival impact of nephroureterectomy for de novo stage IV (nonmetastatic and metastatic) upper tract urothelial carcinoma
2022-06-07
MP04-10: Risk factors of infectious complications after retrograde intrarenal surgery with holmium laser for renal stones
2022-06-07
MP04-09: Comparison of the clinical outcome and treatment cost of proximal ureteral stone removal requiring multiple initial ureteroscopic lithotripsy or extracorporeal shock wave lithotripsy procedures
2022-06-07
<
27
28
29
30
31
32
33
34
35
36
>
/ 121